It is trading at $116.29 a tad higher than $110.71, the 50 day moving average and impressively higher than the 200 day moving average of $100.54. The 50 day moving average went up $5.58 or +5.04% and the 200 day average was up $15.75. Trading volume for Charles River Laboratories Inte was 493K by the end of trading on Tuesday. Trading volume was up 68.83% over the stocks average daily volume.
Investors are a little more bearish on Charles River Laboratories Inte lately as indicated by the motion in short interest. The stock recorded a rise in short interest between September 29, 2017 and October 13, 2017 of 1.06%. Short shares grew 12,980 over that timeframe. The days to cover increased to 4.0 and the percentage of shorted shares is 0.03% as of October 13.
There has been some selling insider activity on Charles River Laboratories Inte (NYSE:CRL) recently. David P. Johst, Corporate Executive VP disclosed the sale of 24,759 shares of CRL stock. The shares were sold on October 5th for an average price of $110.00. Johst now owns $19,938,050 of the stock per the Form 4 SEC filing. Corporate Executive VP Davide Molho disclosed the sale of 6,165 shares of (CRL). The shares were purchased at an average price of $110.00. The Corporate Executive VP now owns $1,820,390 of the stock according to the SEC filing.
Davide Molho, Corporate Executive VP sold $289,371 worth of shares at an average price of $108.46 on September 5th. That brings the Corporate Executive VP’s holdings to $1,794,905 per an SEC filing yesterday.
Here are a few substantial investment firms who have updated their positions. Bbva Compass Bancshares, Inc downsized its stake by shedding 23 shares a decrease of 20.7% as of 09/30/2017. Bbva Compass Bancshares, Inc owns 88 shares valued at $10,000. The value of the position overall is down by 9.1%. As of the end of the quarter Aperio Group, LLC had acquired 1,467 shares growing its position 6.3%. The value of the company’s investment in Charles River Laboratories Inte went from $2,368,000 to $2,687,000 increasing 13.5% quarter to quarter.
As of quarter end Simplex Trading, LLC had sold a total of 1,578 shares trimming its holdings by 65.6%. The value in dollars decreased from $243,000 to $89,000 a change of 63.4% quarter over quarter. Affinity Investment Advisors, LLC cut its ownership by selling 2,910 shares a decrease of 13.8%. Affinity Investment Advisors, LLC controls 18,210 shares worth $1,967,000. The total value of its holdings decreased 7.9%.
On September 19, 2017 RBC Capital started covering CRL by announcing an initial rating of “Sector Perform”. October 9 investment analysts at Jefferies kept the stock rating at “Buy” and raised the price expectation to $130.00 from $96.00.
The P/E ratio is 30.64 and market capitalization is 5.53B. As of the last earnings report the EPS was $3.80 and is expected to be $5.10 for the current year with 47,593,000 shares presently outstanding. Analysts expect next quarter’s EPS will be $1.30 with next year’s EPS projected to be $5.61.
Charles River Laboratories International, Inc., launched on February 3, 1994, is an early-stage contract research company. The Company is involved in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support its clients’ manufacturing activities..